skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

19 Total results for product and free and sample content found

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

20 Jun 2022

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

Topic cell-and-gene-therapy

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

27 Nov 2020

Competitive Strategies Critical As EMA Decides On Kymriah And Yescarta

With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.

Topic Cell & Gene Therapy

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 03 Sep 2020

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Topic cell-and-gene-therapy

Webinar: Is Biopharma Fit For the New Decade?

12 Mar 2020

Webinar: Is Biopharma Fit For the New Decade?

Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

Topic cell-and-gene-therapy policy-and-regulation

Adoptive Cell Therapy

03 Feb 2020

Adoptive Cell Therapy

Citeline recently introduced a new Therapeutic Class called "Adoptive cell therapy", enabling more granular searching capabilities to hone in on this exciting cancer immunotherapy that is expanding the horizon of personalized medicine

Topic cell-and-gene-therapy

Zolgensma Data Integrity Fallout

20 Nov 2019

Zolgensma Data Integrity Fallout

Novartis finds itself facing possible criminal or civil action for admitted data manipulation on its application for Zolgensma, a gene therapy used to treat children with spinal muscular atrophy (SMA) – manipulation disclosed only after FDA approval. Pink Sheet was the first to report on the drug’s loss of EU accelerated assessment, nearly 3 weeks before the pharma giant admitted to submitting falsified data to FDA. Follow the scandal and anticipate its implications on the industry with Pink Sheet’s coverage and timeline.

Topic cell-and-gene-therapy fda

Webinar: Outlook for NASH Therapies and Market Dynamics

04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

Topic cell-and-gene-therapy drug-development-landscape drug-approval

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: